Login to Your Account

Clinic Roundup

Tuesday, June 4, 2013
• Keryx Biopharmaceuticals Inc., of New York, presented updated efficacy and safety data from the Phase III long-term trial of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription